Tuesday, 17 September 2019

Top trends in Transthyretin Amyloidosis (ATTR) Market by 2019

Market Scenario
The Transthyretin (TTR) amyloidosis market is expected to register a sturdy growth during the forecast period.  Transthyretin (TTR) amyloidosis is a medical condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in a body's organs and tissues. It generally affects peripheral neuropathic or autonomic neuropathy system and cardiac system. The cardiac form of Transthyretin (TTR) amyloidosis puts patients at the risk of arrhythmia, cardiomegaly, and orthostatic hypertension. The global ATTR market is likely to exhibit a robust growth during the forecast period due to the probability of rising number of ATTR therapeutic drugs launches, increasing African-American population as they are genetically susceptible to amyloidosis, increasing healthcare awareness among people, and rising average income of individuals. However, the growth of this market can be hindered by stringent regulatory policies, the high cost of ATTR drugs, incorrect diagnosis of ATTR disorders and limitations of clinical trials. Lack of knowledge about this condition and unavailability of advanced diagnostic methods in the middle-income countries are the major challenges to the market.
Top Market Players
  • Alnylam Pharmaceuticals
  • Pfizer
  • Merck
  • Ionis Pharmaceuticals Inc.
  • Corino Therapeutics Inc
  • Arcturus Therapeutics
  • Proclara Bioscience
Market Segmentation                                                                                                                          
Based on region the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. The American region is segmented into North America and South America. Similarly, Europe is segmented into Western Europe and Eastern Europe.
The global Transthyretin (TTR) amyloidosis market is segmented on the basis of disease type, treatment, gender, and end-user. Considering the type of disease, the market is segmented into Transthyretin (TTR) familial amyloid polyneuropathy, Transthyretin (TTR) familial amyloid cardiomyopathy, and others. On the basis of treatment, the market is segmented into small molecules treatment, RNAi therapy,  organ transplantation, and others. Small molecules treatment is further segmented into tafamidis and diflunisal. On gender basis, it is segmented into male and female. According to end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, and others.
Regional Market Summary
Americas dominates the market for Transthyretin (TTR) amyloidosis owing to the increasing prevalence of amyloidosis among adults and older population and rising geriatric population which is a major trigger factor for this disease. For instance, according to a report published by ASCO Journal in 2016 around 4,000 people developed amyloidosis each year in the United States. Thus, this rising patient pool is going to boost up the market growth during the forecast period. Additionally, factors such as increasing government initiatives and funding for research, development in advanced medical treatment options, and rising use of technologically advanced medical diagnostic devices are likely to drive the market. The presence of pharmaceutical giants such as Pfizer, Merck, etc. also propels the market growth in this region.
Asia Pacific is expected to be the fastest growing market. According to a report published by the United Nations in 2015the number of older people aged 60 years or over in the world is predicted to grow by 56% between 2015 and 2030, out of which 66% of the older population would reside in the Asia Pacific region. This makes the region prone to Transthyretin (TTR) amyloidosis as chances of its prevalence increases with the increasing age. Owing to a huge patient pool, a faster adaptation of healthcare technology, government initiatives to increase the healthcare quality, and availability favorable insurance and reimbursement policies, the market growth will be accelerated during the forecast period.  Moreover, key players such as Pfizer, Merck, etc. have been setting up their regional headquarters and manufacturing plants in countries such as Singapore, China, Japan, Korea, and Australia. Thus, the growth curve of the Transthyretin (TTR) amyloidosis market will see a positive trend of growth.
Europe is the second largest market and holds a healthy share in the global Transthyretin (TTR) amyloidosis market. The European market is expected to exhibit robust growth during the forecast period due to major driving factors such as availability of advanced treatment facilities, increasing healthcare expenditure along with growing need for better healthcare infrastructure, and government initiatives of healthcare reform.  It is reported that in the U.K., around 60 new cases of Transthyretin (TTR) amyloidosis are reported annually, and the age-specific incidence rate of it is between 5.1 and 12.8 per million per year. Additionally, established medical device market and capability of inhabitants to afford diagnostics are aiding the market growth. However, the inefficacy of treatment and wrong diagnosis are hampering the market growth of this region.
The Middle East and Africa is expected to show the least growth in the market due to some major factors such as lack of awareness and limited access and availability of treatment facilities. In the Middle East, the United Arab Emirates and Saudi Arabia are the largest markets owing to the development of the healthcare industry and rising availability of specialty care centers. But the market might show a steady growth due to the genetical susceptibility of Africans for transthyretin amyloidosis and government initiatives to improve the quality of healthcare in this region.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Friday, 13 September 2019

Animal Genetics Market Segmentation Detailed Study with Forecast Up To 2019

Market Scenario:
Animal genetics is a branch of genetics that pacts with the study of genetic variation and inheritance, primarily for domestic and wild animals. The Animal Genetics Market is expected to witness tremendous growth owing to as increased adoption of genetic services to prevent genetic diseases and business loss, and rising acceptance of advanced genetic technologies. Other key factors such significant investments in R&D and expansions undertaken by key players are contributing towards the growth of the market. However, challenges such as need for specific breeding programs for breeds with inferior economic performance, and economic sustainability in local breeds is likely to curb the market growth during the forecast period.
For the commercial level, animal genetics is used for services such as DNA typing, genetic disease testing, and genetic trait testing. This methodology uses hybrid population, ontogenetic, and cytological studies for determining the genetic hybridizations. For instance, a genetically modified cow might be able to produce more milk and can be less prone to common cattle diseases, such as clostridial disease, bovine respiratory disease complex, etc., thus, effectively increasing overall profit of the cattle farmers.
The Global Animal Genetics Market size is projected to register a CAGR of 8.4% over the forecast period.
The key factor responsible for influencing this market is increasing consumption of animal-derived protein, growing global population and rapid urbanization, and growing focus on identifying superior breeds have aided the growth of the toxicology testing market. However, factors such as, the high cost of animal testing, stringent regulatory framework for genetic engineering, and lack of skilled professionals and are expected to restrict the market growth during the forecast period.
Key players:
  • Neogen Corporation (US),
  • Genus (UK),
  • URUS (US),
  • EW Group (Germany),
  • Groupe Grimaud (France),
  • CRV Holding B.V. (The Netherland),
  • Topigs Norsvin (Netherlands),
  • Zoetis (US),
  • Envigo (US)
  • Hendrix Genetics BV (The Netherland),
  • Animal Genetics (US),
  • Alta Genetics (US),
  • vetGen (US)
Segmentation:The Global Animal Genetics Market is segmented into animal genetic products, services, and end-user. The Animal Genetics Market, by animal genetic products, the market is segmented into genetic materials and live animals. The live animals are further bifurcated into poultry, bovine, porcine, canine and others. The genetic materials are sub-segmented into semen and embryo. On the basis of services, the animal genetics market is bifurcated into genetic disease tests, DNA typing, gene trait tests, and others. On the basis of end-user, the market is segmented into veterinary hospitals & clinics, diagnostic centers, research centers and institutes, and others
Regional Market Summary 
The Americas is the largest in the market owing to the high acceptance of animal genetics in research, the development in research expenditure along with the increasing acquisition by the market players are also accountable for the growth of the animal genetics market. For instance, in 2018, Neogen completed the acquisition of Livestock Genetic Services, a firm that specializes in genetic evaluations and data management for cattle-breeding organizations. This strategy enhances the company’s in-house genetic evaluation capabilities and further expands the company’s global network of animal genomics laboratories.
The European region is the second largest animal genetics market over the forecast period due to high consciousness about animal wellbeing coupled with increased expenditure on veterinary services in the region. As per a report by the European Pet Food Industry Federation, more than 75 million households in Europe own a pet.
The Asia Pacific region is likely to develop at the uppermost CAGR for the animal genetics market in the years to come. Moreover, the rising veterinary care services both at the veterinary hospital and at community level are expected to influence the market in a positive way.
The Middle East and Africa accounts for the least share due to low per capita income and lack of availability of well-trained healthcare professionals. However, there has been an increasing demand for test accuracy and consistency among end-users and the government in this region that is enhancing the adoption of animal genetic technology in this region.

Browse Complete 90 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/animal-genetics-market-7004
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Endovascular Aneurysm Repair Devices Market, Segments, Growth and Value Chain 2019

Market Scenario
Endovascular aneurysm repair (EVAR) is a collective term for all treatments that are directed to surgically cure an aortic aneurysm located in the patient’s abdomen. Factors such as reduced recovery times, low-cost hospitalization charges, and technological advancements in repair devices are expected to drive the growth of the market.
The global endovascular aneurysm repair devices market is currently dominated by many market players. The key players in the market are engaged in new product launches and strategic collaborations to strengthen its market position. For instance, in April 2018, Vascutek Ltd. and Bolton Medical, subsidiaries of Terumo Corporation, have merged into Terumo Aortic. Combining the aortic companies into a single business, Terumo Corporation aims to grow its presence in the aortic and vascular implants market.
It is estimated that the global endovascular aneurysm repair devices market is expected to record a CAGR ~ 6.4 % during the forecast period of 2018 to 2023.
Key players
  • Cardiatis SA,
  • Cardinal Health,
  • Cook Medical LLC,
  • Endologix, INC.,
  • Jotec GmbH,
  • Medtronic plc,
  • Terumo Corporation,
  • L. Gore & Associates, Inc.,
  • BiFlow Medical Ltd,
  • Boston Scientific Corporation,
  • Braile Biomédica,
  • Endoluminal Sciences Pty Ltd,
  • Endospan Ltd.,
  • Getinge AB,
  • Lemaitre Vascular Inc.
Segmentation
The global endovascular aneurysm repair devices market has been segmented into indication, site, anatomy, and products.
The market, on the basis of indication, has been segmented into the abdominal aortic aneurysm, thoracic aortic aneurysm and others.
The market, based on thoracic aortic aneurysm, has been further segmented into ascending aortic aneurysm, descending aortic aneurysm, thoracoabdominal aortic aneurysm, and thoracic arch aortic aneurysm.
The market, on the basis of the site, has been segmented into infrarenal and pararenal.
The market, based on pararenal site, has been sub-segmented into juxtarenal and suprarenal.
The market, on the basis of anatomy, has been segmented into traditional and complex.
The market, on the basis of products, has been segmented into percutaneous EVAR, fenestrated EVAR, aortic stents and TAA grafts, and others.
Regional Market Summary
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The endovascular aneurysm repair devices market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The Americas is expected to dominate the global endovascular aneurysm repair devices market owing to increasing geriatric population, and well-developed healthcare sector. With the increase in the geriatric population, the prevalence of aneurysms is also expected to rise. The Centers for Disease Control and Prevention (CDC) ranks abdominal aortic aneurysm as one of the top 15 causes of mortality in the United States, but only for those between 85 and 89 years. According to the Centers for Disease Control and Prevention, aortic aneurysms were the primary cause of 9,863 deaths in 2014 in the US.
Europe is expected to hold the second largest position in the global endovascular aneurysm repair devices market. The market growth in this region is attributed to the growing prevalence of aneurysms, availability of funds for research, and favorable reimbursement scenario.
On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to the growing government initiatives for the healthcare sector.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population and continuously developing economies.
Browse Complete 100 Pages Premium Research Report Enabled with 110 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/endovascular-aneurysm-repair-devices-market-6485
       
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Venous Blood Collection Devices Market 2019–By Identifying the Key Market Segments and Key players holding market share

Market Scenario
The Global Venous Blood Collection Devices Market is expected to expand at a CAGR of 9.3% over the forecast period of 2019-2023, reveals Market Research Future (MRFR) in a detailed study.
Venous blood collection devices are vessels used for collection, sampling, and testing blood samples. These devices are easy to handle, provide mechanical protection as well as protection from contamination and radiation. Moreover, these blood collection devices offer the exact filling volume.
The global venous blood collection devices market is driven by the increasing diagnostics and screening for numerous diseases, increasing health awareness leading to growing demand for blood collection devices for sampling, and with the growing preference for disposable products. Product development can be an attractive strategy for expanding the global venous blood collection devices market.
However, restraints that are likely to hinder the growth of the venous blood collection devices market include risks associated with contamination, pressure on prices, and low-quality products from unknown manufacturers. 
The global burden of chronic diseases is increasing at an alarming rate which induces high demand for screening services and consequently boosts the growth of the global venous blood collection devices market. This further complemented by growing disposable income and high health awareness among consumers. To meet the massive demands, medical device manufacturers are endeavoring towards product improvement which jhas resulted in teh devleopment of advanced venous blood collection devices that can be used for safer blood collection. Furthermore expansdion in product oportfolio by key medical device manufacturers have resulted in teh consolidation of teh global venous blood collection devices market. On the other hand, the growth of the market might be undermined by risks related to contamination, pricing pressure, and substandard product from local manufacturers.
Key Players
Some of the key players in the global venous blood collection devices market are Becton, Dickinson and Company (U.S), Bio-Rad Laboratories, Inc. (U.S), NIPRO Medical Corporation (Japan), Qiagen NV (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), Greiner Bio One International GmbH (Greiner Group) (Austria), Terumo Medical Corporation (Japan), Sekisui Chemical Co., Ltd. (Japan), Sarstedt AG & Co (U.S.), F.L. Medical (Italy), Narang Medical (India), Soya Green Tec Co., Ltd. (South Korea), Biosigma (U.S.), Vital Diagnostice (ELITech Group) (U.S.), Improve Medical Technology Co. Ltd. (U.S.), Hongyu Medical (China), SanLI (Myanmar.), KHB (U.S.), Zhejiang Gongdong Medical Technology Co., Ltd. (China), CDRICH (China), Radiometer Medical ApS (Danaher Corporation/ Danrad ApS) (Denmark), Medtronic Plc (U.S.), Fisher Scientific (Thermo Fisher Scientific Inc.) (U.S.), Kabe Labortechnik GmbH (Germany), Allegro Medical Supplies Inc. (Scrip Products Corporation) (U.S.), and others.
Segmentation
The global venous blood collection devices market has been segmented on the basis of type, material, application, and end-user.
On the basis of material, the global venous blood collection devices market is segmented into plastic, glass, stainless steel, ceramic, and others.
On the basis of type, the market is segmented into blood collection tubes, needles, vacuum blood collection system, microfluidic system, micro-container tubes, micro-hematocrit tubes, warming devices, and others. Other devices include venous cannula and blood bags. The blood collection tube is further sub-segmented into plasma separation tube, heparin tube, serum separating tube, EDTA tube, and others.
On the basis of application, the venous blood collection market is segmented into vein blood gas sampling and intraoperative blood salvage. Vein blood gas sampling is further sub-segmented into the diagnosis of disease and acid-base status monitoring.
On the basis of end-user, the global venous blood collection devices market is segmented into hospitals and clinics, the point of care, blood donation centers, diagnostic centers, and others.
Regional Analysis                     
The global venous blood collection devices market consists of four regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Middle Eastern region is expected to grow at a steady pace owing to factors such as rising R&D activities in the healthcare sector and extensive development of the healthcare infrastructure. Gulf nations such as the U.A.E. and Saudi Arabia are projected to drive the Middle Eastern and African market. The government has undertaken various awareness programs for safe blood transfusion procedures which are further improving the health conditions in underdeveloped regions of Africa.
The Americas region accounted for the largest market share of the global venous blood collection devices market owing to the fastest uptake of new surgical techniques and instruments in the North American region, thus driving the venous blood collection devices market. Moreover, the extensive use of screening techniques and high expenditure on health care in the U.S. is driving the market growth. The greater awareness in developed regions along with the good reimbursement scenario drive the Americas venous blood collection devices market.
The European region accounted for the second largest market owing to high income and healthcare penetration. The Asia Pacific region is expected to increase during the forecast period owing to the growing healthcare sector in leading regions such as China and India. The major driving factors of the venous blood collection devices market are the increasing geriatric population, growth in demand for safe blood assortment technologies, increase in demand for improved blood sampling techniques, and increase in preference towards disposable products for the laboratory.
Browse Complete 120 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/venous-blood-collection-devices-market-5761
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Top trends in Bone Biopsy Market by 2019

Market Scenario
According to the World Health Organisation (WHO), cancer was the leading cause of the total number of deaths globally as of 2015 and was responsible for 8.8 million deaths. The most common causal agents identified are cigarettes, cigars, pipes and chewing tobacco. According to the Cancer Research U.K, looking at the lifestyle factors responsible, it has been found that out of 3 diagnosed cases, 1 may be linked to smoking.
Bone biopsy is performed to diagnose various bone disorders such as bone cancer, bone infection, osteoporosis and chronic kidney disease. Nowadays, biopsy procedure has received great importance in oncology as one of the promising methods in cancer diagnostics. The demand for needle biopsy is found to be increasing from last few years.
Increasing prevalence of chronic diseases such as Chronic Kidney Disease (CKD) and demand new diagnostic services drives the market growth. Additionally, increasing research and development activities, technological advancements to identify the causes and risk factors associated with osteopenia and osteoporosis also fuel the market growth of global market.
The Global Bone Biopsy Market is expected to grow at a CAGR of 5.7% during the forecast period.
Key Players in the Global Bone Biopsy Market     
  • C R Bard (U.S.),
  • Becton,
  • Dickinson and Company (U.S.),
  • Braun Melsungen AG,
  • Hologic, Inc. (U.S.),
  • Cook Medical (U.S.),
  • Devicor Medical Products Inc. (U.S.),
  • Argon Medical Inc. (U.S.)
Segmentation      
The global bone biopsy market is segmented on the basis of type, indication and end user.
On the basis of the component, market is segmented into needle biopsy and open biopsy.
On the basis of the application, the market is segmented into bone cancer, bone infection, chronic kidney disease, osteoporosis, and others
On the basis of the end user, the market is segmented into hospital & clinics, surgical centers, diagnostic centers, and others.
Regional Analysis
America holds the first position in the bone biopsy market owing to the rising prevalence of cancer in the U.S. and increasing demand for new cancer diagnostic and treatment services. In Americas, North America is the largest market owing to the presence of key players in healthcare diagnostic industry. The prevalence of osteoporosis is found to be higher in the population over 35 years for age. Changing lifestyle, emphasis on fitness and exercise, and overall development of medical device industry also accelerate the growth of the market.
Europe is the second largest market for bone biopsy. In Europe, there is an increasing demand for advanced bone biopsy devices, and extensive research and development activities by clinical research and academic institutes for cancer diagnosis and treatment. Germany is the largest market followed by France. The market in Germany is driven by increasing demand for specialty care services.
The market in Asia Pacific is expected to grow at the fastest pace and is driven by the high prevalence of chronic disease such as kidney disease, obesity, diabetes and other. India, China, and Japan are major contributors to the growth of the market. This growth is attributed to an increasing demand of technologically advanced medical devices in diagnostic centers and availability of highly qualified medical professional dedicated to research in oncology. Additionally, rising healthcare expenditure and extensive growth of medical device industry also influence the use of medical devices for diagnosis of various diseases such as osteoporosis, diabetes, cancer, and others.
The Middle East & Africa also show a steady rise in the market owing to low technology penetration and increasing awareness about cancer treatment. In the Middle East & Africa, United Arab Emirates captures the largest market share for bone biopsy owing to the availability of better healthcare infrastructure and a wide scope for research. In Africa, the market also shows a positive growth owing to development of healthcare system in African countries, and increasing demand for primary care services.
Browse Complete 110 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/bone-biopsy-market-5341
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Wednesday, 11 September 2019

Connective Tissue Disease Market 2019 Share, Trend, Segmentation and Forecast to 2023

Connective tissues are a group of cellular congregations that provide support and structure to the human body. Connective tissue disease is a group of disorders which involves these protein rich tissues. Protein rich tissues play an important role of supporting organs and other parts of the body. Connective tissue disorders involves multiple organs and organ systems such as, skin, joints, muscles, lungs, kidneys, eyes, heart, gastrointestinal tract, and blood vessels. More than 200 disorders affect the connective tissues. According to a study published in Pan African Medical Journal in 2017, it is found that mixed connective tissue disorders are more frequent among Asians, and in the African population. It is also reported that among Asian population, the condition is more prevalent in China, and Japan. In the European region, the disorder is more prevalent in Italy, Hungary, Norway, and Poland.
Developments in the treatment of connective tissue diseases (CTDs) have been improved considerably, and the global connective tissue diseases market is slated to grow at a promising CAGR of 11.5% over the forecast period of 2017-2023. The cause of the disease is unknown and there's no cure for connective tissue disease yet, but medications are present to manage the signs and symptoms. CTDs include a large number of disorders which can affect different organs of the body. There is broad variability in disorders among patient suffering from CTDs.
It is estimated that connective tissue disease market is expected to grow at a CAGR 11.5% during the forecast period of 2017-2023.
A significant increase in the research and development efforts to find treatment and cure for CTDs have aided the growth of the market. Various therapy trials are underway which have been able to identify promising novel approaches to treat CTDs and are expected to boost the growth of the market. Rising prevalence of CTDs across the globe, especially in women has propelled the growth of the market. Additionally, support from governments across the world along with funds for R&D from the private industry is also a key driver of the growth of the market. With the increase in awareness and acceptance among the general population about connective tissue diseases, the diagnosed and drug-treated population will increase which will positively impact the market. Rising expenditure on healthcare, high unmet medical needs of the current treatment and growing prevalence of CTDs in Asia and Africa are expected to promote the growth of the market.  However, the growth of the market might be hindered by lack of a knowledgeable workforce, inadequate research and development infrastructure, lack of funds in middle and low-income countries.
Key Players
Some of key the players in the market are
  • Abbott Laboratories
  • Bayer AG
  • Hoffmann-La Roche Ltd
  • Pfizer
  • AutoImmune Inc.
  • Johnson & Johnson
  • Amgen Inc.
  • AstraZeneca
  • Eli Lilly and Company
  • Biogen
  • LUPIN
Segmentation
The connective tissue disease market is segmented on the basis of diagnosis, treatment, and end-user.
On the basis of diagnosis, market is segmented into physical examination, X-ray examination, ANA (Antinuclear Antibody Test), and others.
On the basis of treatment, market is classified into non-steroidal anti-inflammatory drugs (NSAIDs), cortisone drugs/steroids, antimalarial drugs, cytotoxic drugs, and others
On the basis of end-user, market is segmented into hospital, diagnostic clinics, and others.
Regional Analysis
The Americas dominate the connective tissue disease market owing to the rising awareness among people, and increasing healthcare expenditure. As per the facts suggested by the Centers for Disease Control and Prevention (CDC), out of the total annual healthcare expenditure, 86% is for people with chronic health conditions in the United States.
Europe holds the second position in the connective tissue disease market. It is expected that the support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the market in Europe.
Asia Pacific is the fastest growing market connective tissue disease, owing to a huge patient pool, developing healthcare technology, and rising healthcare expenditure in some countries within this region. According to the Australian Institute of Health and Welfare, in the years 2015 to 2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than expenditure of 2014–15.
The Middle East & Africa has the lowest market for connective tissue disease due to lack of technical knowledge and poor medical facilities. 
Browse Complete 85 Pages Premium Research Report Enabled with 66 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/connective-tissue-disease-market-4977
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Top trends in Augmented Bone Graft Market by 2019

According to the British Editorial Society of Bone & Joint Surgery, bone is the second most common transplanted tissue after blood with an estimated 2.2 million grafting procedures worldwide annually as recorded in 2015. This development has been fuelled by the increasing cases of fractures and accidents around the world.
The Global market of Augmented Bone Graft is expected to grow at a CAGR of approximately 7.8% during the forecast period 2017-2023.
Augment Bone Graft is a combination drug/device product used for repairing the bone and reviving its regenerative properties. It is used as an alternative to autograft in arthrodesis of the ankle or hindfoot indicating the need for supplemental graft material. The use of augment bone graft eliminates the need for a second surgery to harvest autologous bone, thereby avoiding donor site morbidity. According to the National Health Interview Survey, in 2012, around 126 million adults were affected by this disease in the U.S. According to the Labor Force Survey (LFS), about 553,000 cases were registered for all work-related musculoskeletal disorder out of the total of 1,243,000 cases.
Allografts and bovine-derived bone graft products dominate the augmented bone graft market. These materials have variations in particle size which is their main drawback. The recent technological trend is to replace these natural materials with alloplastic bone grafts such as ceramics and polymers as they can be manufactured to the precise size and characteristics.
There has been increasing acceptance of bone grafting procedures which drives the market for augmented bone graft products. Many healthcare professionals have started using these bone grafts, especially in tertiary care centers and specialty hospitals which may promote and increase the demand for augmented bone graft. These bone graft works in a unique way to stimulate three key processes of early bone healing.
Various other factors such as, increasing advancement in technology, and rising adoption rate of new technology continuously contribute to the growth of this market. Despite these developments, high cost of surgeries and ethical issues related with bone grafting procedures may hamper the growth of the market. For instance, a study conducted by BMC Medical Ethics states that in a sample of 100 patients, about 20% of the patients refuse to accept allografts for their grafting surgery.
Additionally, stringent regulations obstruct the growth of bone grafts market and inadequate reimbursement policies for bone grafting also hampers the growth of global bone grafts market. Rapid product launches and increasing mergers and acquisitions between bone graft systems manufacturing companies are some of the major trends in the global bone grafts market.
The Key Players
  • Zimmer Holdings, Inc.
  • BioMimetic Therapeutics LLC
  • Wright Medical Technology, Inc.
  • Stryker Corporation, Smith & Nephew Plc
  • RTI Surgical, Inc.,
  • Olympus Biotech Corporation
  • NuVasive, Inc.
  • NovaBone Products LLC
  • Medtronic, Inc.
  • LifeNet Health, Inc.
  • Integra LifeSciences Holdings Corporation
  • Exactech, Inc.
  • DePuy Spine, Inc.
  • Synthes Inc.
  • DePuy Synthes Companies
  • Biomet, Inc.
Segmentation
The Augmented Bone Graft is segmented on the basis of products, application, and end-users.
On the basis of application, the market is segmented into the Craniomaxillofacial, Dental, Foot & Ankle, Joint Reconstruction, Long Bone, and Spinal Fusion
On the basis of product, the market is segmented into the Allografts, Bone Grafts Substitutes, and Cell-based Matrices. The Allografts segment is further sub divided into Machined Allografts and Demineralized Bone Matrix. The Bone Grafts Substitutes is also sub categorized as Bone Morphogenic Proteins (BMP) and Synthetic Bone Grafts.
On the basis of end-user, the market is segmented into hospitals, clinics, ambulatory surgical centers and others.
Browse Complete Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/augmented-bone-graft-market-4961  
Regional Analysis
The Global Augmented Bone Graft Market consists of countries namely America, Europe, Asia Pacific, and the Middle East.
North America dominated the global augmented bone graft market owing to the increasing healthcare expenditure in North America since 2016. Canadian healthcare specifically was stressed by an advancing demographic move. The increase of insurance coverage because of health care reform (Affordable Care Act) in the United States additionally prompted an expansion in health care spending. In 2016, healthcare organizations found liberation from a special tax on medical devices (Medical Device Excise Tax). The United States Congress put off the tax for a long two years in 2015.
For Europe, the healthcare spending has expanded slightly in Germany. Neverthelss, the orthopedic biologics market including the bone graft substitute market has been determined by solid strong competition and price pressure. While volume of sales and the scope of new treatment techniques are on the ascent, net revenues in the German market are declining. Western Europe continues to see a need to save money on healthcare because of a slight drop in financial growth and obstinate economic pressure.
Healthcare spending in Asia expanded in 2016 due to an extension of state health care programs and the increasing affluence of the population. India, in specific, saw an expansion in spending due to a government resolution to enhance healthcare services.
Furthermore in the Middle East & Africa the spending for healthcare was also increased. This was essentially because of elections in a few nations, (for example, Ghana, Niger, Uganda, Zambia and Somalia), healthcare growth and population growth. Awareness for medicinal technology likewise expanded extraordinarily. Due to of low local production, the region is dependent on imported medicinal products. The import standard in numerous nations is 80% to 90%.

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com